Blood
Articles in this Issue
First results from the Phase 1 study of APL-4098, an oral potent GCN2 inhibitor for the treatment of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) and Myelodysplastic Syndromes (MDS)/AML
Abstract Background: Patients with R/R AML and MDS/AML have a very poor prognosis, with most patients dying from disease-related complicatio...
Peripheral T-cell lymphomas: Real-world insights into clinical features and prognosis
Abstract Introduction: Peripheral T-cell lymphomas (PTCLs) are associated with poor prognosis. Subtypes include peripheral T-cell lymphoma n...
From fit to frail: Effectiveness and safety of fixed-dose carfilzomib in the treatment of multiple myeloma – a single-center, real world evidence in China
Abstract Background Carfilzomib, a second-generation proteasome inhibitor, has been dosed twice weekly (27/56 mg/m²) [1]...
ST-101: Manufacturing GMP-compliant HLA-compatible definitive human hematopoietic stem and progenitors cells from iPSCs using Piezo1 agonists for clinical transplant
Abstract Making transplantable human hematopoietic stem cells (HSCs) from induced pluripotent stem cells (iPSCs) has been a longstanding obj...
DYRK1A controls CD47 endocytic degradation and leukemia immune surveillance
Abstract AML is an aggressive blood cancer with no effective immunotherapies. One mechanism by which AML evades immune surveillance is by up...
Impact of clonal hematopoiesis and BRAF mutation status on clinical outcomes in melanoma patients treated with immune checkpoint inhibitors
Abstract Context Clonal hematopoiesis (CH) is an age-associated phenomenon which has been implicated in vascular diseases and hematologic ma...
Cytokine-medated expansion of clonal hematopoiesis after CART therapy
Abstract Chimeric antigen receptor (CAR) T-cells are highly effective against relapsed and refractory B cell and plasma cell malignancies, b...
Unleashing intrinsic inflammation in AML using therapeutic cytokines overcomes pro-survival pathways and induces deep and durable remission In Vivo.
Abstract Acute myeloid leukemia (AML) remains a clinical challenge due to high relapse rates, primarily driven by therapy-resistant leukemic...
Chimeric antigen receptor T cells in real-world care of multiple myeloma: Patient characteristics and healthcare resource utilization
Abstract Introduction: Chimeric antigen receptor T-cell(CAR-T) therapies targeting B-cell maturation antigen are now established in the trea...
Belumosudil in pediatric patients with steroid-refractory chronic graft-versus-host disease
Abstract Belumosudil has been introduced to treat steroid-refractory chronic graft-versus-host disease (SR-cGVHD) in adult patients. Similar...
Aiming at immune fitness in cancer: Longitudinal functional profiling to predict clinical outcome
Abstract Cancer patients experience immune dysfunction due to both cancer and its treatment. Immune dysfunction leads to impaired responses...
A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial
Abstract In previously untreated, medically fit, patients with chronic lymphocytic leukemia, research is focused on developing fixed-duratio...
Preemptive Rituximab in patients with ADAMTS13 relapse in thrombotic thrombocytopenic purpura: A systematic review
Abstract Introduction: ADAMTS13, a cleaving protease, deficiency/relapse during thrombotic thrombocytopenic purpura (TTP...
Clinical characteristics and prognostic analysis of 52 cases of ALK-positive anaplastic large cell lymphoma
Abstract Objective: ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) is a rare T-cell lymphoma. Anthracycline-based combination chemo...
Incidence and risk factors of chronic kidney disease (CKD) in lymphoma survivors
Abstract Background:Recent advances in the treatment of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) have significantly improved lon...
Machine learning-derived, comprehensive “Geno-Immunome” of bone marrow failure syndromes reveals complex immunogenetic interactions with clinical implications
Abstract Several triggers have been stipulated for idiopathic bone marrow failure (BMF) syndromes, but they are likely to occur/be pathogeni...
A phase III, multicenter, randomized, placebo controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult sickle cell disease patients with frequent vaso-occlusive crises: The sparkle study
Abstract Crizanlizumab, a P-selectin blocker, has been approved by the US Food and Drug Administration to reduce the frequency of vaso-occlu...
Safety and efficacy of triple vs quadruple therapy in transplant ineligible multiplemyeloma patients – a meta-analysis of randomized controlled trials
Abstract Introduction In newly diagnosed multiple myeloma (NDMM), many patients are ineligible for stem cell transplant due to advanced age,...
Distinct inflammatory and immune recovery patterns after CD19-directed CAR T-cell therapy in SLE and B-cell lymphoma
Abstract Introduction: While CD19-directed Chimeric Antigen Receptor (CAR) T-cell therapy is now established as a standard of care in relaps...
PIEZO1 activation controls erythropoiesis through calpain-dependent degradation of HSP70
Abstract Background The discovery of PIEZO1 gain-of-function mutations in hereditary xerocytosis (HX) has highlighted the role of mechanotra...
Exploring the relationship between health-related stigma and perceived discrimination among adults with sickle cell disease
Abstract Introduction Health related stigma and perceived discrimination are distinct yet interconnected psychosocial stressors that signifi...
Characterization of IGHV subgroups and their prognostic relevance in CLL
Abstract Introduction: Immunoglobulin heavy chain variable region (IGHV) somatic hypermutation (SHM) status is a strong prognostic marker in...
PRMT1 drives platelet metabolic reprogramming, thromboinflammation, and antiplatelet drug resistance
Abstract Background: Platelet hyperactivity and reduced responsiveness to antiplatelet therapies are major contributors to thrombotic compli...
Clinical outcomes in adult AML with KMT2A rearrangements: A comparative analysis with R/R KMT2Ar and NPM1-mutated AML from the Mayo Clinic
Abstract Background: KMT2A-rearranged acute myeloid leukemia (KMT2Ar AML) is characterized by chromosomal translocation involving KMT2A gene...
A novel dll4 enhancer regulates sinusoidal niche-mediated HSC proliferation and maintenance
Abstract The sinusoidal vascular niche plays a critical role in maintaining hematopoietic stem and progenitor cells (HSPCs), and its dysfunc...